NFATC2 and neuroblastoma: Furthermore, it is possible that therapeutic treatment could be helpful for the MES status of NB (PRRX1, NFATC2, RAC2, VAV1), which showed a higher degree of inflammatory characterization and possible immunological vulnerability.